Loading the security overview…
Where the tokens are
Standardised from the company’s filings, newest period first, labelled with the company’s own fiscal calendar. A line the company does not report is left off rather than shown as zero; margins and free cash flow are worked out here, and only where every input is present.
| Line item | Q1 FY272026-06-30 | Q4 FY262026-03-31 | Q3 FY262025-12-31 | Q2 FY262025-09-30 | Q1 FY262025-06-30 | Q4 FY252025-03-31 | Q3 FY252024-12-31 | Q2 FY252024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.44M | $2.52M | $2.00M | $1.57M | $2.17M | $7.57M | $9.02M | $4.48M |
| Gross profit | $1.44M | $2.52M | $2.00M | $1.57M | $2.17M | $7.57M | $9.02M | $4.48M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Research and development | $202.02M | $198.95M | $165.38M | $164.57M | $152.92M | $145.24M | $141.60M | $143.07M |
| Selling, general and administrative | $165.53M | $158.25M | $175.07M | $143.13M | $134.02M | $147.09M | $141.55M | $202.88M |
| Operating expenses | $367.44M | −$412.72M | $341.15M | $307.80M | $287.09M | $292.54M | $283.40M | $346.19M |
| Operating income | −$365.99M | $415.24M | −$339.15M | −$306.23M | −$284.92M | −$284.97M | −$274.38M | −$341.71M |
| Operating margin | -25380.9% | 16477.8% | -16966.1% | -19492.9% | -13130.0% | -3764.4% | -3042.6% | -7636.0% |
| EBITDA | −$365.79M | −$354.36M | −$338.46M | −$305.31M | −$283.82M | −$283.54M | −$271.46M | −$336.87M |
| Interest income | $36.92M | $41.18M | $43.27M | $45.34M | $48.32M | $54.62M | $61.85M | $69.77M |
| Income before taxes | −$294.56M | $454.10M | −$290.37M | −$159.04M | −$269.26M | −$203.05M | −$234.51M | −$224.38M |
| Income taxes | −$3.96M | $98.35M | $23.33M | $7.00M | $4.65M | $49.32M | −$25.57M | $12.46M |
| Net income | −$290.61M | $355.74M | −$313.70M | −$166.04M | −$273.91M | −$252.38M | $118.08M | −$279.92M |
| Net margin | -20153.0% | 14116.8% | -15692.9% | -10569.0% | -12622.6% | -3333.9% | 1309.3% | -6255.3% |
| EPS, basic | −$0.26 | $0.42 | −$0.38 | −$0.17 | −$0.33 | −$0.29 | $0.23 | −$0.31 |
| EPS, diluted | −$0.26 | $0.42 | −$0.38 | −$0.17 | −$0.33 | −$0.31 | $0.23 | −$0.31 |
| Diluted shares | 720.78M | 717.36M | 696.86M | 680.95M | 680.29M | 661.77M | 722.72M | 735.47M |
Figures describe Roivant Sciences shares, not any token. As of Aug 6, 2026, from Massive's standardised financials. The company reports these figures; a token's issuer holds the shares and reports nothing of its own here.